natgillin/translations-raw huggingface dataset:
a mouse k light chain constant region gene, wherein the plurality of contiguous unrearranged functional hVλ gene segments and the plurality of contiguous unrearranged functional hJλ gene segments are operably linked to the mouse k light chain constant region gene such that the unrearranged light chain variable region is capable of rearranging to form a rearranged human λ light chain variable region and the mouse expresses antibodies comprising a light chain comprising a variable domain encoded by the rearranged human λ light chain variable region and a constant domain encoded by the mouse k light chain constant region gene; and 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
Use of an enriched conglutin-Y protein extract from lupin seeds having a % by weight of conglutin-Y between 10 and 30%, or a conglutin-Y protein in the form of a diet supplement to improve endurance performance. 
Primjena obogaćenog ekstrakta konglutin-ɣ-proteina iz sjemena lupine (vučike), naznačena time, da sadrži 10 do 30 težinskih postotaka konglutin-ɣ ili jedan konglutin-ɣ-protein u obliku dodatka prehrani za poboljšanje izdržljivosti.
An anti-FcRn antibody or FcRn-binding fragment thereof according to any one of claims 1 to 4 which has a binding affinity for human FcRn of 100pM or less when measured at pH6 and at pH7.4. 
Anti-FcRn antitijelo ili njegov fragment koji se vezuje za FcRn prema bilo kojem patentnom zahtjevu od 1 do 3, naznačen time, što je antitijelo ili vezujući fragment konjugiran na polimer, primjerice odabran iz škroba, albumina i polietilenglikola.
In DD 257442 the solvent content of the coating is reduced by modifying the alkyd binder with a dicyclopentadiene fatty acid ester derivative. 
U DD 257442 je sadržaj otapala smanjen zamjenom alkilnog veziva s esterskim derivatom diciklopentadien masne kiseline.
In some embodiments, Ring A is optionally substituted with substituents selected from the group consisting of halogen, C1-4 haloalkyl, and C1-4 alkyl. 
U nekim oblicima, Prsten A je po izboru supstituiran supstituendima izabranim iz skupine koju čine halogen, C,.4 haloalkil i C,.4 alkil.
A compound in accordance with claim 12 wherein R2 and R3 are independently H or methyl. 
Spoj prema zahtjevu 12, naznačen time što su Ri R* nezavisno H ili metil.
The mixture was cooled and the precipitate that formed was collected by vacuum filtration, washed with hexanes and dried to give a light pink solid. 
Smjesa se hladi i precipitat koji tako nastaje se prikuplja pomoću vakuum filtriranja, ispere heksanom i suši čime se dobiva svjetloružičasta krutina.
a step of moving the manufacture away by means of suction through the upper axial end of a lower spacing tube that faces, with its upper axial end, below said handling device. 
- = korak uklanjanja gotovog proizvoda (50) usisavanjem preko gornjeg aksijalnog kraja donje odstojne cijevi (4) koja je okrenuta svojim gornjim aksijalnim krajem ispod navedenog uređaja za rukovanje (2).
an antibody light chain comprising an antibody light chain sequence selected from SEQ ID NOs: 35, 54 and 55. 
(11) lakog lanca čija sekvenca odgovara sekvenci lakog lanca antitijela izabranoj iz grupe koju čine SEQ ID NO:
A process according to claim 17, wherein said silicone oils are oils based on polyphenyl-methylsiloxane, polydimethylsiloxane, or a 1:1 mixture of polydimethylsiloxane and polydiphenylsiloxane. 
- osilikonska ulja, posebice ulja na bazi polifenil-metilsiloksana, polidimetilsiloksana ili 1:1 smjese polidimetilsiloksana i polidifenilsiloksana,
They are particularly suitable for the treatment of inflammatory, allergic and autoimmune disorders, such as asthma and chronic bronchitis, allergic, vasomotor and viral rhinitis, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, chronic inflammatory diseases of the bowel (Crohn's disease and ulcerative colitis), glomerulonephritis, psoriasis, rash, acute and chronic cystitis, hepatic cirrhosis, glomerulopathies and pulmonary fibrosis, arteriosclerosis, both acute and chronic pain, septic, allergic and post-traumatic shocks, hepatic cirrhosis by hepatorenal syndrome, hypotension, alopecia, or as anticancer and antiangiogenetics. 
Oni su posebno pogodni za tretman upalnih, alergijskih, i autoimunih poremećaja kao što je astma i kronični bronhitis, alergijski, vazomotorni i virusni rinitis, kronična opstruktivna plućna bolest (COPD), reumatoidni artritis, kronična upalna bolest crijeva (Crohnova bolest i ulcerativni kolitis), glomerulonefritis, psorijaza, osip, akutni i kronični cistitis; hepatička ciroza, glomerulopatije i plućna fibroza, arteroskleroza, akutna i kronična bol, septički, alergijski 1 postraumatski šokovi i hepatička ciroza od hepatorenalnog sindroma, hipotenzija 1 alopecija ili kao antikancerogeno i antiangiogenetsko sredstvo.
In one embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 10; a heavy chain variable region CDR2 of SEQ ID NO: 24; a heavy chain variable region CDR3 of SEQ ID NO: 38; a light chain variable region CDR1 of SEQ ID NO: 52; a light chain variable region CDR2 of SEQ ID NO: 66; and a light chain variable region CDR3 of SEQ ID NO: 80. 
(1) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 10; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 24; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 38; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 52; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 66; 1 CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 80;
a second promoter operably linked to a nucleic acid encoding an immunogenic heterologous polypeptide. 
(b) drugog promotora operativno povezanog s nukleinskom kiselinom koja kodira imunogeni heterologni polipeptid.
Some of these agents include HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV cell fusion inhibitors, HIV integrase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, budding and maturation inhibitors, immunomodulators, and anti-infectives. 
Neka od ovih sredstava obuhvaćaju inhibitore vezanja HIV-a, CCR5 inhibitore, CXCR4 inhibitore, inhibitore HIV stanične fuzije, inhibitore HIV integraze, nukleozidne inhibitore HIV Teverzne transkriptaze, ne-nukleozidne inhibitore HIV reverzne transkriptaze, inhibitore HIV proteaze, inhibitore pupanja i sazrijevanja, imunomodulatore i anti-infektivna sredstva.
It is further disclosed that at least a portion of the free liquid of the soaked ligno-cellulosic biomass stream may be drained before separation step e). 
Proces iz bilo kojeg od patentnih zahtjeva 7 do 8, gdje je barem dio slobodne tekućine struje natopljene lignocelulozne biomase izdreniran prije koraka odvajanja e).
Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with photoionization (APPI) ion source and Shimadzu LC-8A/SLC-10A LC system. 
Analitički LC-MS podaci dobiveni su pomoću PE Sciex API 150EX instrumenta opremljenog s fotoionizacijskim (APP) ionskim izvorom i Shimadzu LC-8A/SLC-10A LC sistemom.
Other ways are disclosed in U.S. Pat. 
US (73) Nositelj patenta:
Dihydrospiro-[cycloalkylamine]-pyrimidone derivatives represented by formula (I) or salts thereof, solvates thereof or hydrates, wherein X, Y, R1, R2, R3, o, n, p, q are as defined hereabove and R4 represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group or a C1-4 alkoxy group; represent another object of the invention. 
Dihidrospiro[cikloalkilamin/pirimidonski derivati, prikazani formulom (1), ili njihove soli, njihovi solvati ili hidrati, gdje X, Y, RI, R2, R3, 0, 1, p, q su defininirani kao gore, a R4 predstavlja atom vodika, Ci. alkoksikarbonilnu skupinu, Cig alkilnu skupinu, izborno supstituiranu s 1 do 4 supstituenta, koje se bira između atoma halogena, hidroksilne skupine ili C;.4 alkoksi skupine; te predstavljaju joše jedan cilj ovog izuma.
or a pharmaceutically acceptable salt thereof. The compound according to claim 7, which is: 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide, 
Spoj prema zahtjevu 7, naznačen time, da je to: 3-amino-6-metoksi-5-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)- amid, ili njegova farmaceutski prihvatljiva sol.
The method according to one of claims 1 - 6, wherein the precious metals contained in the non-magnetic residues include gold, silver, platinum, palladium, rhodium, ruthenium, iridium and/or osmium. 
Postupak prema jednom od patentnih zahteva 1-4, naznačeno time, da plemeniti metali sadrže zlato, srebro, platinu, paladij, rodij, rutenij, iridij i/ili osmij.
The combined ether extract was extracted with 4% aqueous ammonium hydroxide (5 x 200 ml.). 
Spojeni eterski ekstrakt se ekstrahira sa 4% vodenim amonij-hidroksidom (5 x 200 ml.).
reacting Compound 3 with a first aqueous base followed by neutralizing to obtain a primary SNS-595 hydrate; 
(b) reakciju Spoja 3 sa prvom vodenom bazom, nakon čega slijedi neutraliziranje da se dobije primarni SNS-595 hidrat;
As it can be seen from the table, all the compounds tested are more potent as vasorelaxants than the reference product. 
Iz tablice se može vidjeti da su svi ispitani spojevi jači kao vazorelaksanti nego usporedbeni proizvod.
The aim of the present invention is to provide a sheet for packaging food that is capable of obviating the problems and drawbacks of known types of sheet. 
Cilj predloženog izuma je osigurati foliju za pakiranje hrane koja može odstraniti probleme i nedostatke poznatih tipova folija.
Also, in places with only little consumption e.g. 
Također, u mjestima s malom potrošnjom, npr.
An example of the procedure is given below: 
Datum podnošenja europske prijave patenta:
Tanker according to any of claims 6 to 13, wherein the tank module (11) comprises walls enclosing an inner space, wherein preferably the internal space is divided in a plurality of tanks, preferably by means of internal walls; wherein preferably the walls (17) of the tank module are made of stainless steel. 
Tanker prema bilo kojem od zahtjeva 6 do 13, naznačen time da modul spremnika (11) sadrži stjenke koje okružuju unutrašnji prostor, pri čemu je poželjno unutrašnji prostor podijeljen u mnoštvo spremnika, poželjno pomoću unutrašnjih stjenki; pri čemu su poželjno stjenke (17) modularnog spremnika izrađene od nehrđajućeg čelika.
Since a controlled heating is necessary in order not to create overshoot depending on the oven a heating ramp of 5° C. is useful. 
Kako je kontrolirano zagrijavanje neophodno da se bi dobilo pregrijavanje koje ovisi o grijaču, rampa za zagrijevanja od 5 "C je korisna.
with the proviso that when the at least one polymer is not recycled from polymer waste in accordance with any one of claims 1-7, the coating additionally comprises a second compound selected from the group consisting of one or more fatty acids and one or more salts of a fatty acid, and combinations thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što obloga dodatno sadrži drugi spoj, kojeg se bira između jedne ili više masnih kiselina 1 jedne ili više soli masnih kiselina, te njihovih kombinacija.
Example 7: Flushing via Laser Doppler 
Primjer 7: Crvenilo via Laser Doppler
The method of claim 1, wherein the patient has failed or is intolerant to at least one other migraine headache prophylactic therapy. 
Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time što pacijent nije uspio ili ima netoleranciju na barem jednu drugu profilaktičku terapiju migrenske glavobolje.
The pharmaceutical composition of 25, wherein the steroidal anti-inflammatory agent is a corticosteroid or a pharmaceutically acceptable salt or solvate thereof. 
Farmaceutski pripravak iz patentnog zahtjeva 5, naznačen time, da je steroidno protu-upalno sredstvo kortikosteroid ili njegova farmaceutski prihvatljiva sol ili solvat.
The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. 
Doza spoja upotrijebljena u liječenju gore navedenih poremećaja ovisit će na uobičajeni način o težini poremećaja, težini oboljelog, te o drugim sličnim čimbenicima.
A crystalline compound according to any one of claims 1 to 4 for use in treating an ischemic-related condition. 
Farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1 do 10 za uporabu u liječenju stanja povezanog s ishemijom.
The immunoconjugate of any one of claims 1 to 8, comprising a polypeptide sequence of SEQ ID NO: 301, a polypeptide sequence of SEQ ID NO: 303, and a polypeptide sequence of SEQ ID NO: 231. The immunoconjugate of any one of claims 1 to 9, consisting of a mutant IL-2 polypeptide and an IgG1 molecule, joined by a linker sequence. 
SEK.: 303, te polipeptidnu sekvencu ID BR. SEK.: Imunokonjugat prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da se sastoji od mutacijskog polipeptida IL-2 i molekule IgG,-a povezanih sekvencom povezivača.
reacting compound 11 with to produce the compound and 
(1i) reakciju spoja 11 sa da se proizvede spoj
Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents. 
Tablete i kapsule za oralnu primjenu mogu biti u obliku jedinice doziranja, te mogu sadržavati uobičajene pomoćne tvari, poput veziva, punila, maziva za tabletiranje, sredstva za raspadanje, te prihvatljiva sredstva za vlaženje.
Pet-ether (30-40 °C) (56 ml) was added and the suspension was stirred for fifteen minutes at laboratory temperature. 
Doda se petrolej eter (30-40 *C) (56 ml) i suspenzija se miješa tijekom petnaest minuta pri laboratorijskoj temperaturi.
that a distributor plate at one of its sides is brought into contact with the dosing pistons; 
ovođenje raspodjelne ploče na jednoj njenoj strani u doticaj s dozirnim klipovima;
represents hydrogen, halogen, methyl, hydroxy, methoxy, benzyloxy, cyano, or amido; 
RS predstavlja vodik, halogen, metil, hidroksi, metoksi, benziloksi, cijano ili amido;
on the same front surface, between the bore 178 and the groove 177, a plurality of vertical needles 173 for piercing the upper membrane or foil 209, as well as vertical nozzles 175 to inject water under pressure into the capsule 200, as this shall be better explained further on in this description; a device 180 (see FIGS. 4 to 6) for actuating the lever 114, which comprises: 
- na istoj prednjoj površini, između provrta 178 i utora 177, nalazi se više okomitih igala 173, za probadanje gornje membranc ili folije 209, kao i okomite mlaznice 175, za ubacivanje vode pod tlakom u kapsulu 200, što će biti bolje objašnjano niže u ovom opisu; d) nedaj 180 (vidjeti Slike 4 do 6) za pokretanje poluge 114, koji sadrži: jezgru ili klip 181, načinjen od magnetskog materijala, primjerice u slučaju permanentog magneta;
Most typically, the alkane sulfonic acid is methane sulfonic acid and is present in an amount of between 15 and 35 wt %, and/or the chelator is EDTA (ethylene diamine tetraacetic acid) and is present in an amount of between 1 and 10 wt %. As noted before, it should be appreciated that the active material lead need not necessarily be desulfirized. 
Međuproizvod proizvodnje sukladno patentnom zahtjevu 10 pri čemu je alkan sulfonska kiselina metan sulfonska kiselina 1 prisutna je u količini između 15 i 35 wt%, ili pri čemu je kelator etilen diamin tetraoctena kiselina (EDTK) i prisutan je količini između 1 1 10 wt%, ili pri čemu aktivni materijal olova nije prethodno desulfiziran.
iv-a) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 257 ng/ml +/- 59 ng/ml following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or 
Vildagliptina od 257 ng/mL +/- 59 ng/mL nakon oralne primjene navedenog dozirnog oblika pacijentu koji nije bio tretiran vildagliptinom prije navedene primjene i pri čemu je pacijent pod uvjetima posta, i/ili kruti oralni dozirni oblik koji sadrži oko 150 mg vildagliptin slobodne baze ili odgovarajuću količinu njegove farmaceutski prihvatljive soli, te podlogu, pri čemu navedeni dozirni oblik pruža srednju vrijednost Cmax.
The lower inner element 14 comprises longitudinal reinforcing 24 bar and a latitudinal reinforcing bar 26. 
Donji unutarnji element 14 sadržava šipku 24 za uzdužno pojačanje i šipku 26 za pojačanje po širini.
According to one embodiment, the isolated host cell as described above is chosen from Trichoderma, Aspergillus, Neurospora, Humicola, Myceliophthora, Chrysosporium, Penicillium, Fusarium, Thermomonospora, Bacillus, Pseudomonas, Escherichia, Clostridium, Cellulomonas, Streptomyces, Yarrowia, Pichia and Saccharomyces. 
Izolirana stanica domaćin u skladu s patentnim zahtjevom 5, naznačena time što se bira između organizama Trichoderma, Aspergillus, Neurospora, Humicola, Penicillium, Fusarium, Thermomonospora, Myceliophihora, Chrysosporium, Bacillus, Pseudomonas, Escherichia, Clostridium, Cellulomonas, Streptomyces, Yarrowia, Pichia i Saccharomyces.
The sub LNG supply line may include a gas-liquid separator configured to separate a heavy hydrocarbon component from the LNG so as to adjust a methane number of the fuel to a value necessary for the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 3, naznačen time što pomoćna linija za slanje LNG (1.24) sadrži separator plina od tekućine (46), podešen za razdvajanje teške ugljikovodične komponente od LNG, kako bi se podesilo metanski broj goriva do vrijednosti potrebne za pomoćni motor.
The peptide compound according to claim 1 for the treatment of a condition in which selective agonism of the AT2 receptor is desired and/or required, wherein the condition is diabetes, myocardial infarction, renal hypertension, stroke, alopecia, an inflammatory lung disorder, fibrosis, or wherein said condition requires augmentation of erythropoiesis. 
Peptidni spoj prema bilo kom od patentnih zahtjeva 1 do 10, za upotrebu u liječenju i/ili prevenciji stanja u kome je selektivni agonizam prema AT2 receptoru poželjan i/ili potreban.
The method of claim 1, comprising administering the composition together with an ophthalmically acceptable balanced salt solution comprising one or more electrolytes selected from the group consisting of potassium chloride, sodium bicarbonate, potassium bicarbonate, calcium chloride, magnesium chloride, a sodium citrate, hydrochloric acid, and sodium hydroxide. 
Farmaceutski oblik za uporabu prema bilo kojem od zahtjeva 1 do 9, gdje oftalmički prikladna uravnotežena fiziološka otopina sadrži barem tri različita elektrolita izabrana iz skupine koja obuhvaća natrijev fosfat, natrijev klorid, kalijev klorid, natrijev bikarbonat, kalijev bikarbonat, kalcijev klorid, magnezijev klorid, natrijev acetat, natrijev citrat, klorovodičnu kiselinu i natrijev hidroksid.
Other objects and advantages will be apparent to those skilled in the art from the following detailed description taken in conjunction with the examples and the appended claims. DETAILED DESCRIPTION An object of the present invention is to provide a recombinant microorganism producing chondroitin, defined as a linear glycosaminoglycan consisting of alternating residues of D-glucuronic acid (GlcUA) and N-acetyl-D-galactosamine (GalNAc) bound by B1-3 linkage and B1-4 linkage respectively, characterized in that in said microorganism a gene encoding an enzyme responsible for the addition of fructose residues to the chondroitin back-bone is inactivated. 
Rekombinantni mikroorganizam koji proizvodi hondroitin, definiran kao nerazgranati glikozaminoglikan, kojega čine izmjenjujući ostaci D-glukuronske kiseline (GICUA) i N-acetil-D-galaktozamina (GalNAc), vezani vezama f13 (GIcUA - GalNAc) i B1-4 (GaINAc > GIcUA), naznačen time što je navedeni mikroorganizam izveden iz mikroorganizma koji pripada skupini s antigenom K, gdje je u navedenom mikroorganizmu izvorno prisutan gen kfoE, koji kodira enzim odgovoran za dodavanje fruktoznih ostataka na nerazgranatu okosnica hondroitina, inaktiviran potpunom ili djelomičnom delecijom ili supstitucijom navedenog gena ili disrupcijom insercijom dodatnog nukleotidnog slijeda, te gdje navedeni gen kfoE kodira protein koji se bira iz skupine koju čine:
The device of any one of Claims 1 and 3 to 5, wherein the abrasive tip (20) comprises a material selected from the group consisting of conductive and non-conductive materials. 
Uređaj prema bilo kojem od zahtjeva od 1 i 3 do 5, naznačen time što abrazivna glava (20) sadrži materijal odabran iz skupinc koja obuhvaća provodljivc i neprovodljive materijale.
Furthermore, many of the compounds according to the present invention are inactive or only weakly active in a hERG assay. 
Nadalje, mnogi od spojeva prema ovom izumu ne pokazuju aktivnost, ili su vrlo slabo aktivni u testu hERG.
Het is a monocyclic heterocycle selected from the group of N -phenoxypiperidinyl, piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl and benzo[1,3]dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, hydroxy, alkyl, alkyloxy, and Ar-carbonyl; 
Het je monociklički heterocikal koji je odabran iz skupine koja sadrži N-fenoksipiperidinil, piperidinil, pirolil, pirazolil, imidazolil, furanil, tienil, oksazolil, izoksazolil, tiazolil, izotiazolil, piridinil, pirimidinil, pirazinil i piridazinil; ili je biciklički heterocikal koji je odabran iz skupine koja sadrži kinolinil, kinoksalinil, indolil, benzimidazolil, benzoksazolil, benzizoksazolil, benzotiazolil, benzizotiazolil, benzofuranil, benzotienil, 2,3-dihidrobenzo[1,4]dioksinil i benzo[1,3]dioksolil; a svaki monociklički ili biciklički heterocikal može proizvoljno biti supstituiran sa 1, 2 ili 3 supstituenta, a svaki supstituent je neovisno odabran iz skupine koja sadrži halo, hidroksi, alkil, alkiloksi, te Ar-karbonil;
the C1-C6-alkyl optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, hydroxy, nitro, oxo, amino, cyano, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, and heterocyclyl 
-C6-alkil je opcijski supstituiran s jednim ili više supstituenata neovisno odabranima iz skupine koju sačinjavaju karboksi, halo, hidroksi, nitro, okso, amino, cijano, alkiloksikarbonil, alkilkarboniloksi, alkiloksi, karbociklil i heterociklil;
The container assembly according to claim 1, wherein a part of the container assembly comprises a transparent part for viewing inside the container. 
Sklop posude prema bilo kojem od prethodnih Zahtjeva, gdje dio sklopa (300) posude sadrži transparentni dio namijenjen omogućavanju pogleda na unutrašnjost posude (1).
at least one seal configured to enclose either or both the proximal end and the distal end of the chamber. 
izvlačenje vanjskog čepa iz najmanje jedne komore i infuziju preparata na osnovi stanica u komoru; i